30/09/2026
This case study is wild
Man told he has between 6 months and 2.5 years to live
Severe, end-stage atherosclerosis with multiple stents
Stumbles upon obscure treatment in a random mouse study
Orders it from some online company and starts injecting it intravenously
Tracks everything. After less than 2 months:
- Right carotid plaque down by 36% and 27%
- Triglycerides down by 75%
Still alive, and his name is Kyle Hodgetts
Goes on to coauthor and publish his n= 1 data in two papers
The “obscure treatment” = Beta-Cyclodextrin (hydroxypropyl-B-cyclodextrin)
A molecule with such widespread use that it essentially can’t be patented, and is currently being investigated in early trials for its efficacy on a wider scale. Indeed, it can be purchased by anyone online.
And it is entirely possible that it turns out to be a major challenge to multi-billion dollar statin industry, and it has very few reported side effects.
Kyle eventually set up a company making a version of cyclodextrin which can be administered rectally, due to its poor oral bioavailability.
The simplified proposed mechanism of action:
- Binds cholesterol esters and sterols, carries them out of the body (via urine)
- Dissolves cholesterol crystals
- Restore endothelial nitric oxide synthase
- Activates the LXR pathway
Of course, prevention via diet and lifestyle and then targeted supplementation with things like nattokinase, niacin, aged garlic extract, CoQ10, etc would obviously be the route to take in the early stages.
However, in the terminal stage, an intervention like this might end up being a major game changer.
References:
- 10.1126/scitranslmed.aad6100
- PMID: 27053774
- 10.29011/2575-7083.100262
- 10.1371/journal.pone.0338635
- 10.1016/j.atherosclerosis.2025.119217
- 10.1016/j.atherosclerosis.2025.119640
- NCT06813339
Case reports: https://www.heartfixer.com/Cyclodextrin.htm